These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18668841)

  • 21. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
    Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.
    Gu GZ; Xia HM; Pang ZQ; Liu ZY; Jiang XG; Chen J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):449-56. PubMed ID: 21251889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapeutic effect of methyl-salazosulphapyridine versus salazosulphapyridine in active ulcerative colitis. A double-blind controlled trial.
    Riis P; Jarnum S; Holtz A; Folkenborg O; Kristensen M; Binder V
    Scand J Gastroenterol; 1979; 14(6):647-51. PubMed ID: 43585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relapse-preventing effect of methyl-salazosulphapyridine compared to salazosulphapyridine during long-term treatment of ulcerative colitis. A double-blind controlled trial.
    Riis P; Binder V; Kristensen M; Folkenborg O; Holtz A; Jarnum S
    Scand J Gastroenterol; 1979; 14(3):257-60. PubMed ID: 35824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.
    Fleig WE; Laudage G; Sommer H; Wellmann W; Stange EF; Riemann J
    Digestion; 1988; 40(3):173-80. PubMed ID: 2906888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical effect of various 5-ASA preparations in ulcerative colitis].
    Kruis W; Pohl C
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():26-30. PubMed ID: 10194945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis.
    Sutherland LR; Roth DE; Beck PL
    Inflamm Bowel Dis; 1997; 3(2):65-78. PubMed ID: 23282747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Miglioli M; Barbara L
    Gut; 1991 Aug; 32(8):929-31. PubMed ID: 1885075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
    Sutherland LR; May GR; Shaffer EA
    Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.
    Sutherland L; Roth D; Beck P; May G; Makiyama K
    Cochrane Database Syst Rev; 2000; (2):CD000543. PubMed ID: 10796555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
    Schroeder KW; Tremaine WJ; Ilstrup DM
    N Engl J Med; 1987 Dec; 317(26):1625-9. PubMed ID: 3317057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of salicylazosulphapyridine, sulphapyridine and its metabolites in serum and urine.
    Ahnfelt NO; Modin R; Odell ML; Ohlson U
    J Pharm Biomed Anal; 1986; 4(2):261-9. PubMed ID: 16867622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.
    Willoughby CP; Piris J; Truelove SC
    Scand J Gastroenterol; 1980; 15(6):715-9. PubMed ID: 7010522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis.
    Sutherland L; Roth D; Beck P; May G; Makiyama K
    Cochrane Database Syst Rev; 2000; (2):CD000544. PubMed ID: 10796556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.